

MAKING THE HEADLINES

MBI updates No. 9 - September 2025

MBI gains spotlight on two major US news programs


Recently, two major US news outlets featured MBI's efforts to spare children from toxic treatments and move closer to a cure.



Gold September — Childhood Cancer Awareness Month — opened with **MBI's founder speaking with Bret Baier at FOX NEWS on September 1st.**




He discussed funding challenges in pediatric cancer research and shared his journey after his son's medulloblastoma diagnosis, which led to founding MBI with Dr. Roger J. Packer and launching two clinical trials in record time.

On August 7, **MBI founder Fernando Goldsztein spoke on MSNBC's Morning Joe** about the initiative's global impact, highlighting its consortium of 16 leading institutions and top scientists advancing pediatric brain tumor research.



.....

The MBI model — called a ‘new playbook for curing rare childhood diseases’ by MIT — is becoming a global reference in rare disease research. By uniting speed, scientific excellence and a worldwide network of experts, MBI accelerates access to new therapies for children who cannot wait. Every child deserves a future.



These institutions unite scientific excellence and global collaboration.
New partners — Seattle Children's and the Children's Hospital of Philadelphia — strengthen our efforts.

Consortium meeting: Expanding the network

In July, at the latest Cure Group 4 Consortium meeting in Washington, D.C., Seattle Children's and the Children's Hospital of Philadelphia joined the network, expanding it to 16 laboratories worldwide. Their addition strengthens CAR T-cell research already underway at Children's National and other sites, as the Consortium prepares to launch multiple trials for Group 4 tumors this fall.



The meeting also highlighted progress on MBI's first two FDA-approved trials at the University of Florida: **Dr. Duane Mitchell's MATCHPOINT trial**, which has enrolled its first patient, and Dr. Elias Sayour's mRNA vaccine trial, soon to begin patient recruitment.


.....

nature Cure Group 4 Consortium researchers also recently co-authored groundbreaking scientific articles in Nature and Nature Biomedical Engineering.

The studies revealed how medulloblastomas develop resistance and introduced a new way to make tumors more responsive to immunotherapy — advances that could directly benefit children with few treatment options.

You can read them here:

- **Oncogene aberrations drive medulloblastoma progression, not initiation.**
- **Sensitization of tumours to immunotherapy by boosting early type-I interferon responses enables epitope spreading.**




Lemonade for a Cure

Seven-year-old Kennedy Ransom has already led several fundraising campaigns for pediatric cancer. In 2025, with the support of her family and community, she dedicated her efforts to MBI, setting up her lemonade stand throughout the summer. **On August 28, she proudly handed Dr. Roger J. Packer a \$2,000 check** — double her original goal — to support the Cure Group 4 Consortium.

We are incredibly grateful to Kennedy, her family and everyone helping us fulfill our mission—to support the world's best research that will find a cure for medulloblastoma.

♥ Testimonials





The Ransom family

“Saying yes to donating to MBI was an effortless decision, fueled by our desire to create a brighter future for Kennedy and all children affected by cancer. We make this donation in honor of all of the kids who lost the battle in hopes that one day that number reaches zero.”

.....

“For families navigating the uncertainty of a rare diagnosis, this effort represents more than research; it's a tangible model of hope and progress. The inspiring work led by MBI sets a powerful example of how determination and innovation can reshape the future for children and families facing rare diseases.”



Michelle Riley-Brown
MHA, FACHE


President & Chief Executive Officer
Children's National Hospital

“Children's National Hospital is proud to stand beside the Medulloblastoma Initiative in fighting for children and families. We are grateful for the passion and visibility you bring to such important work.”

MBI's Voice in The Washington Post

The Washington Post featured our founder's voice in its letters to the editor section.

.....



Report No. 9 - September, 2025

Produced by The Medulloblastoma Initiative and Children's National Hospital

Team

Fernando Goldsztein: Founder
Mauro Dorfman: Strategic leader
Iago Paz: Design and social media
Alessandra Chang: Project manager
Claudia Buchweitz: Team leader
Martina Fischer: Philanthropy & relationships manager

Advisory Board

Paula Puppi
Claudio Galvão de Castro
Ricardo Sales
Claudia Buchweitz
Mauro Dorfman
Fernando Goldsztein

Children's National Hospital Foundation

Amanda Ranalli: Associate Vice President, Major, Principal and International Giving
Andrew Miller: Director of Development, Neurosciences & Behavioral Medicine
Paige Mulry: Development Coordinator, Major Gifts and International Advancement
Emma Younger: Development Assistant

www.mbinitiative.org

martina.fischer@mbinitiative.org

[f themedulloblastomainitiative](#)

[medulloblastomainitiative](#)

[in medulloblastomainitiative](#)

© 2025 The Medulloblastoma Initiative – All rights reserved.

Photos: Pexels.com / Unsplash / Canva

